Optic nerve repair could treat glaucoma:
This article was originally published in Clinica
Mice treated with Boston Life Sciences' central nervous system growth factor Axogenesis Factor 1 (AF1) have re-grown severed axons within the optic nerve, suggesting that AF1 could be used to treat blindness caused by glaucoma. Degenerative injury to the optic nerve destroys the vision of glaucoma sufferers. This is the first time that injection of a single nerve growth factor has resulted in optic nerve regeneration, says Boston Life Sciences. The company's chief scientific officer, Dr Marc Lanser said, "These exciting data suggest that AF1 has the potential to be a totally novel approach to the treatment of glaucoma."
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.